{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:21:18Z","timestamp":1787743278723,"version":"build-2784847793"},"reference-count":26,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"BeOne Medicines Ltd","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,7,28]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with unresectable stage III non-small cell lung cancer (NSCLC) have an unmet need for new therapies that improve survival. This phase III trial investigated the safety and efficacy of concurrent ociperlimab and tislelizumab plus concurrent chemoradiotherapy (cCRT) in treatment-na\u00efve patients with stage III NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this phase III, multicenter, randomized, multiarm, open-label trial, patients with unresectable stage III NSCLC received concurrent ociperlimab plus tislelizumab and cCRT, followed by ociperlimab plus tislelizumab (arm A), tislelizumab and cCRT, followed by tislelizumab (arm B), or cCRT, followed by durvalumab (arm C) (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04866017\">NCT04866017<\/jats:ext-link>\n                      ). Objectives were to compare progression-free survival (PFS), overall survival (OS), objective response rate (ORR), duration of response, disease control rate, clinical benefit rate, time to death or distant metastasis (TTDM), and safety and tolerability for arms A versus C, B versus C, and A versus B.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>63 patients were randomized to arms A (N=22), B (N=19), and C (N=22) prior to early trial termination. In A, B, and C, respectively, 95.5% (21\/22), 84.2% (16\/19), and 95.5% (21\/22) were current or former smokers, and 68.2% (15\/22), 73.7% (14\/19), and 68.2% (15\/22) had PD-L1 expression in tumor cells of \u22651%. Median PFS (95%\u2009CI) was not reached (NR) (6.3\u2013not estimable (NE)) in A, 15.0 months (7.4 to NE) in B, and 10.4 months (5.7 to NE) in C. Median OS and TTDM were NR in any arm. ORR (95%\u2009CI) was 68.2% (45.1%\u201386.1%) in A, 68.4% (43.4%\u201387.4%) in B, and 59.1% (36.4%\u201379.3%) in C; all responses were partial responses. Treatment-emergent adverse events (TEAEs) occurred in all patients; in arms A, B, and C, respectively, pneumonitis occurred in 18.2% (4\/22), 5.6% (1\/18), and 9.1% (2\/22) of patients, and interstitial lung disease occurred in 13.6% (3\/22), 11.1% (2\/18), and 0% of patients, of which the majority of events for each were grade 1\/2. Grade \u22653 treatment-related TEAEs occurred in 68.2% (15\/22), 66.7% (12\/18), and 68.2% (15\/22) of patients in arms A, B, and C, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There was a trend toward improved efficacy when adding tislelizumab with or without ociperlimab to cCRT followed by tislelizumab with or without ociperlimab compared with cCRT followed by durvalumab; however, efficacy data were for descriptive purposes only. No unexpected or new safety signals were identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013527","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:45:20Z","timestamp":1787741120000},"page":"e013527","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04866017","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04866017","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ligang","family":"Xing","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-1424","authenticated-orcid":false,"given":"Terufumi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4798-8899","authenticated-orcid":false,"given":"Antonin","family":"Levy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Gustave Roussy, Villejuif, France"},{"name":"Gustave Roussy, Inserm U1030, Universit\u00e9 Paris-Saclay, Villejuif, France"},{"name":"Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paris Saclay, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Billy W","family":"Loo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA"},{"name":"Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1303-0447","authenticated-orcid":false,"given":"Alexander I","family":"Spira","sequence":"additional","affiliation":[{"name":"Virginia Cancer Specialists, US Oncology Research, NEXT Oncology Virginia, Fairfax, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5602-0487","authenticated-orcid":false,"given":"Jie","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjiao","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3576-6909","authenticated-orcid":false,"given":"Qingsong","family":"Pang","sequence":"additional","affiliation":[{"name":"Departments of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Badin","sequence":"additional","affiliation":[{"name":"Baptist Health Medical Group, Lexington, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"D\u00f3mine G\u00f3mez","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, University Hospital Fundacion Jimenez Diaz, Instituto de investigaci\u00f3n sanitaria FJD (IIS-FJD), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Chongqing University Cancer Hospital and Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yao","sequence":"additional","affiliation":[{"name":"Statistics Department, BeOne Medicines Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5131-2311","authenticated-orcid":false,"given":"Li","family":"Yang","sequence":"additional","affiliation":[{"name":"Clinical Development, BeOne Medicines Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3824-2713","authenticated-orcid":false,"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"2026082603451310000_14.8.e013527.1","unstructured":"American Cancer Society . Cancer facts & figures 2023. 2023. Available: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2023\/2023-cancer-facts-and-figures.pdf [Accessed 9 Dec 2024]."},{"key":"2026082603451310000_14.8.e013527.2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.21037\/tlcr.2020.03.40","article-title":"Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival","volume":"10","author":"Casal-Mouri\u00f1o","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"2026082603451310000_14.8.e013527.3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx222"},{"key":"2026082603451310000_14.8.e013527.4","unstructured":"AstraZeneca . IMFINZI prescribing information. 2025. Available: https:\/\/drd9vrdh9yh09.cloudfront.net\/50fd68b9-106b-4550-b5d0-12b045f8b184\/9496217c-08b3-432b-ab4f-538d795820bd\/9496217c-08b3-432b-ab4f-538d795820bd_viewable_rendition__v.pdf [Accessed 30 Mar 2025]."},{"key":"2026082603451310000_14.8.e013527.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937"},{"key":"2026082603451310000_14.8.e013527.6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01308"},{"key":"2026082603451310000_14.8.e013527.7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02821","article-title":"Intrinsic expression of immune checkpoint molecule TIGIT could help tumor growth in vivo by suppressing the function of NK and CD8+ T cells","volume":"9","author":"Zhou","year":"2018","journal-title":"Front Immunol"},{"key":"2026082603451310000_14.8.e013527.8","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13407"},{"key":"2026082603451310000_14.8.e013527.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.02.005"},{"key":"2026082603451310000_14.8.e013527.10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80445"},{"key":"2026082603451310000_14.8.e013527.11","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01800-3","article-title":"Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials","volume":"22","author":"Chu","year":"2023","journal-title":"Mol Cancer"},{"key":"2026082603451310000_14.8.e013527.12","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.1143","article-title":"1017P AdvanTIG-105: phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)","volume":"33","author":"Yu","year":"2022","journal-title":"Annals of Oncology"},{"key":"2026082603451310000_14.8.e013527.13","doi-asserted-by":"crossref","first-page":"S375","DOI":"10.1016\/j.jtho.2022.07.645","article-title":"P08.01-073 AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC","volume":"17","author":"Kumar","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2026082603451310000_14.8.e013527.14","doi-asserted-by":"crossref","unstructured":"Frentzas S , Meniawy T , Kao SCH , et al . 126P AdvanTIG-105: phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS). 2022;16:100238. doi:10.1016\/j.iotech.2022.100238","DOI":"10.1016\/j.iotech.2022.100238"},{"key":"2026082603451310000_14.8.e013527.15","unstructured":"American Joint Committee on Cancer . AJCC cancer staging manual.8th edn. New York: Springer, 2017."},{"key":"2026082603451310000_14.8.e013527.16","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-CT255","article-title":"Abstract CT255: AdvanTIG-204: A phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) + tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC)","volume":"84","author":"Gong","year":"2024","journal-title":"Cancer Res"},{"key":"2026082603451310000_14.8.e013527.17","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1200\/JCO-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small-cell lung cancer: the phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026082603451310000_14.8.e013527.18","doi-asserted-by":"crossref","first-page":"100808","DOI":"10.1016\/j.iotech.2024.100808","article-title":"65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT)","volume":"24","author":"Peters","year":"2024","journal-title":"Immuno-Oncol Technol"},{"key":"2026082603451310000_14.8.e013527.19","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamaoncol.2024.1897","article-title":"Atezolizumab before and after chemoradiation for unresectable stage III non-small-cell lung cancer: a phase II nonrandomized controlled trial","volume":"10","author":"Ross","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026082603451310000_14.8.e013527.20","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1016\/j.cllc.2022.04.003","article-title":"Rationale and design of the phase III KEYLYNK-012 study of pembrolizumab and concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for stage III non-small-cell lung cancer","volume":"23","author":"Jabbour","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"2026082603451310000_14.8.e013527.21","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1016\/j.ijrobp.2021.07.1203","article-title":"SKYSCRAPER-03: a phase III, open-label, randomized study of atezolizumab plus tiragolumab compared with durvalumab in patients with locally advanced, unresectable, stage III NSCLC who have not progressed after platinum-based concurrent chemoradiation","volume":"111","author":"Dziadziuszko","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026082603451310000_14.8.e013527.22","doi-asserted-by":"crossref","first-page":"S947","DOI":"10.1016\/j.annonc.2021.08.1794","article-title":"1190TiP SKYSCRAPER-03: Phase III, open-label randomised study of atezolizumab + tiragolumab vs durvalumab in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based concurrent chemoradiation (cCRT)","volume":"32","author":"Dziadziuszko","year":"2021","journal-title":"Ann Oncol"},{"key":"2026082603451310000_14.8.e013527.23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8609","article-title":"Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)","volume":"41","author":"\u00d6zg\u00fcro\u011flu","year":"2023","journal-title":"JCO"},{"key":"2026082603451310000_14.8.e013527.24","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1080\/14796694.2024.2354160","article-title":"PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer","volume":"20","author":"Barlesi","year":"2024","journal-title":"Future Oncol"},{"key":"2026082603451310000_14.8.e013527.25","first-page":"100911","article-title":"AdvanTIG-204: a phase 2, randomized, open-label study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy versus tislelizumab and concurrent chemoradiotherapy versus concurrent chemoradiotherapy in first-line limited-stage SCLC","volume":"6","author":"Gong","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"2026082603451310000_14.8.e013527.26","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1016\/j.cllc.2021.07.005","article-title":"CheckMate 73L: a phase 3 study comparing nivolumab plus concurrent chemoradiotherapy followed by nivolumab with or without ipilimumab versus concurrent chemoradiotherapy followed by durvalumab for previously untreated, locally advanced stage III non-small-cell lung cancer","volume":"23","author":"De Ruysscher","year":"2022","journal-title":"Clin Lung Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:45:26Z","timestamp":1787741126000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,26]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/jitc-2025-013527"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013527","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}